Bluejay Diagnostics provided a corporate update for Q3 2026, highlighting the completion of enrollment for its SYMON-II clinical study and the establishment of an alternative manufacturing site ahead of schedule. The company reported a cash balance of $7.38 million and targets an FDA 510(k) submission for its Symphony IL-6 platform in the first half of 2027.
Bluejay Diagnostics reported a net loss of $6.26 million for the nine months ended September 30, 2026, compared to $5.42 million in the prior year period. The company strengthened its cash position to $7.38 million through private placements and warrant exercises, while continuing to invest heavily in research and development for its diagnostic platform.
Bluejay Diagnostics implemented a 1-for-4 reverse stock split of its common stock, effective November 3, 2026. The split reduces the number of outstanding shares from approximately 4.47 million to 1.12 million to maintain compliance with Nasdaq listing requirements. Trading will continue under the ticker 'BJDX' with a new CUSIP number.
Bluejay Diagnostics achieved a critical contractual milestone under its license agreement with Toray Industries by establishing a manufacturing site for its Symphony cartridges at SanyoSeiko Co. in Japan. This milestone was reached ahead of the October 23, 2026 deadline and is part of a broader strategy to build a resilient supply chain alongside its U.S. manufacturing partner, ALURIS Sciences.
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, which is evaluating the Symphony IL-6 Test for mortality risk in sepsis patients. The study includes 777 evaluable patients with an 18% mortality rate, providing a diverse dataset to support the company's planned regulatory submission. The data showed that non-survivors had higher baseline illness severity, with septic shock present in 56.4% of that group.